News Savara Inc.

Equities

SVRA

US8051111016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/05/2026 BST			5-day change	1st Jan Change
5.120 ^USD	-2.10%		-3.40%	-15.09%

04-24	Oppenheimer Adjusts Price Target on Savara to $11 From $9, Maintains Outperform Rating	MT
04-15	Savara announces the U.S. Food & Drug Administration (FDA) has extended the review period for the molgramostim inhalation solution (molgramostim) biologics license application (BLA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP)	RE

All News

Mentions Relevance

05-11	Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference	BU
04-24	Oppenheimer Adjusts Price Target on Savara to $11 From $9, Maintains Outperform Rating	MT
04-17	Savara Announces New Employment Inducement Grant	BU
04-15	Savara announces the U.S. Food & Drug Administration (FDA) has extended the review period for the molgramostim inhalation solution (molgramostim) biologics license application (BLA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP)	RE
04-15	Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application	MT
04-15	Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
04-15	Savara Announces the U.S. Food & Drug Administration Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application in Autoimmune Pulmonary Alveolar Proteinosis	CI
04-14	Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference	BU
04-08	Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency Has Accepted the MOLBREEVI Marketing Authorisation Application for Autoimmune Pulmonary Alveolar Proteinosis	AQ
04-07	Savara Inc. Announces MHRA Accepts Molbreevi Marketing Authorisation Application for Autoimmune PAP	CI
04-07	Savara Says UK Health Care Body Accepts Submission of Marketing Authorization Application for Molbreevi	MT
04-07	Savara announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the Molbreevi* marketing authorisation application (MAA) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP)	RE
04-07	Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
03-30	Savara Says EMA Validates Marketing Authorization Application for Molbreevi to Treat Lung Disease	MT
03-30	Savara Inc. Announces Validation Of Marketing Authorization Application For Molbreevi In Autoimmune Pulmonary Alveolar Proteinosis	CI
03-30	Savara : Corporate Presentation	PU
03-30	Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
03-13	Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025	CI
03-13	Savara Q4 Loss Unchanged From Year Earlier	MT
03-13	Savara Inc Enters into Agreement of Lease for New Headquarters	CI
03-13	Savara : Corporate Presentation	PU
03-13	Earnings Flash (SVRA) Savara Posts Q4 Loss $0.13 a Share, vs. FactSet Est of $0.12 Loss	MT
03-13	Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update	BU
03-09	Savara Provides Regulatory Update on the MOLBREEVI Development Program in Autoimmune Pulmonary Alveolar Proteinosis	AQ
03-06	Savara Says FDA Letter Indicates No Advisory Committee Meeting Planned for Molbreevi Application	MT